[go: up one dir, main page]

BR9907995A - Métodos imunológicos para modular miostatina em sujeitos vertebrados - Google Patents

Métodos imunológicos para modular miostatina em sujeitos vertebrados

Info

Publication number
BR9907995A
BR9907995A BR9907995-0A BR9907995A BR9907995A BR 9907995 A BR9907995 A BR 9907995A BR 9907995 A BR9907995 A BR 9907995A BR 9907995 A BR9907995 A BR 9907995A
Authority
BR
Brazil
Prior art keywords
myostatin
vertebrate subjects
immunological methods
methods
vertebrate
Prior art date
Application number
BR9907995-0A
Other languages
English (en)
Inventor
Christopher A Barker
Mohamad Morsey
Original Assignee
Biostar Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biostar Inc filed Critical Biostar Inc
Publication of BR9907995A publication Critical patent/BR9907995A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

MéTODOS IMUNOLóGICOS PARA MODULAR MIOSTATINA EM SUJEITOS VERTEBRADOS São relatados métodos e composições imunológicas para reduzir a atividade de miostatina em sujeitos vertebrados. As composições incluem imunógenos peptídicos de miostatina, multímeros de miostatina e/ou imunoconjugados de miostatina capazes de induzir uma resposta imune num sujeito vertebrado ao qual as composições são administradas. Os métodos são úteis para o tratamento de uma ampla variedade de distúrbios.
BR9907995-0A 1998-02-19 1999-02-19 Métodos imunológicos para modular miostatina em sujeitos vertebrados BR9907995A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7521398P 1998-02-19 1998-02-19
PCT/CA1999/000128 WO1999042573A1 (en) 1998-02-19 1999-02-19 Immunological methods to modulate myostatin in vertebrate subjects

Publications (1)

Publication Number Publication Date
BR9907995A true BR9907995A (pt) 2001-05-15

Family

ID=22124285

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9907995-0A BR9907995A (pt) 1998-02-19 1999-02-19 Métodos imunológicos para modular miostatina em sujeitos vertebrados

Country Status (18)

Country Link
US (2) US6369201B1 (pt)
EP (3) EP1770162B1 (pt)
JP (1) JP2002504326A (pt)
KR (1) KR20010041111A (pt)
AR (1) AR019818A1 (pt)
AT (2) ATE419353T1 (pt)
AU (1) AU765014B2 (pt)
BR (1) BR9907995A (pt)
CA (2) CA2323607C (pt)
CY (2) CY1108074T1 (pt)
DE (2) DE69940230D1 (pt)
DK (2) DK1770162T3 (pt)
ES (3) ES2318654T3 (pt)
IL (1) IL137831A0 (pt)
NZ (1) NZ506911A (pt)
PT (2) PT1770162E (pt)
WO (1) WO1999042573A1 (pt)
ZA (1) ZA991369B (pt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393682B1 (en) * 1993-03-19 2008-07-01 The Johns Hopkins University School Of Medicine Polynucleotides encoding promyostatin polypeptides
US7566768B1 (en) * 1995-10-26 2009-07-28 The Johns Hopkins University School Of Medicine Promyostatin peptides and methods of using same
US6465239B1 (en) * 1993-03-19 2002-10-15 The John Hopkins University School Of Medicine Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species
JPH09507829A (ja) 1993-03-19 1997-08-12 ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン 増殖分化因子−８
US5994618A (en) 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
US7332575B2 (en) 1994-03-18 2008-02-19 The Johns Hopkins University School Of Medicine Growth differentiation factor-8 nucleic acid and polypeptide from aquatic species, and transgenic aquatic species
CA2359242C (en) * 1999-01-21 2009-12-08 Metamorphix, Inc. Growth differentiation factor inhibitors and uses therefor
HUP0201861A3 (en) 1999-07-20 2004-07-28 Pharmexa As Method for down-regulating gdf-8 activity
ZA200003786B (en) 1999-07-30 2002-01-21 Pfizer Prod Inc Myostatin regulatory region, nucleotide sequence determination and methods for its use.
EP1593689A3 (en) * 2000-01-18 2006-04-05 Ovita Limited Myostatin and mimetics thereof
US7037501B2 (en) * 2001-01-04 2006-05-02 Regents Of The University Of Minnesota Myostatin immnoconjugate
TWI329129B (en) 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
BR0307907A2 (pt) * 2002-02-21 2011-07-05 Wyeth Corp gasp1: proteìna contendo domìnio de folistatina
PL374966A1 (en) * 2002-02-21 2005-11-14 Wyeth Follistatin domain containing proteins
EP1578928B1 (en) * 2002-09-16 2010-03-17 The Johns Hopkins University Metalloprotease activation of myostatin, and methods of modulating myostatin activity
AR047392A1 (es) * 2002-10-22 2006-01-18 Wyeth Corp Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
US20040223966A1 (en) * 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
ATE496938T1 (de) * 2002-12-20 2011-02-15 Amgen Inc Myostatin hemmende bindungsstoffe
JP5110877B2 (ja) 2003-06-02 2012-12-26 ワイス・エルエルシー 神経筋障害を処置するための、コルチコステロイドと組み合わせたミオスタチン（ｇｄｆ８）インヒビターの使用
JP2007535912A (ja) * 2003-12-31 2007-12-13 シェーリング−プラウ・リミテッド 中和エピトープベースの増殖増強性ワクチン
JP4688483B2 (ja) 2004-04-15 2011-05-25 株式会社テクノネットワーク四国 フォリスタチン変異体ポリペプチド
JP2008509927A (ja) * 2004-08-12 2008-04-03 ワイス Ｇｄｆ−８阻害剤を使用する、糖尿病、肥満、および心臓血管疾患のための併用療法
EP1799709B1 (en) * 2004-09-30 2012-04-04 ORICO Limited Myostatin isoform
AU2005323087A1 (en) * 2004-12-30 2006-07-13 Schering-Plough Pty. Limited Neutralizing epitope-based growth enhancing vaccine
NZ538097A (en) * 2005-02-07 2006-07-28 Ovita Ltd Method and compositions for improving wound healing
BRPI0609439A2 (pt) * 2005-03-23 2010-04-06 Wyeth Corp detecção de uma resposta imunológica a agentes moduladores de gdf-8
JP2009518422A (ja) * 2005-12-06 2009-05-07 アムジェン インコーポレイテッド ミオスタチン・アンタゴニストの使用
AU2013231037B2 (en) * 2006-08-03 2016-05-12 Myostin Therapeutics Pty Ltd Myostatin antagonists
BRPI0715072A2 (pt) * 2006-08-03 2013-06-25 Orico Ltd antagonistas de miostatina
CN101511871B (zh) 2006-09-05 2012-07-18 伊莱利利公司 抗肌肉生长抑制因子抗体
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
SI2170396T1 (sl) 2007-08-03 2017-04-26 Summit (Oxford) Limited Kombinacije zdravil za zdravljenje duchennove mišične distrofije
KR100857861B1 (ko) * 2007-10-15 2008-09-11 주식회사 바이오리더스 Ｍｙｏ－２ 펩타이드 중합체와 마이오스타틴의 융합단백질표면발현용 벡터 및 상기 벡터로 형질전환된 미생물
US9873739B2 (en) 2012-08-01 2018-01-23 Ikaika Therapeutics, Llc Mitigating tissue damage and fibrosis via latent transforming growth factor beta binding protein (LTBP4)
CN104391628B (zh) * 2014-04-02 2018-02-23 贵阳朗玛信息技术股份有限公司 进程切换方法及装置
EP2960653A1 (en) * 2014-06-24 2015-12-30 Stichting Kwaliteitsgarantie Vleeskalversector Diagnostic kit and method for the identification of the manipulation of muscle mass in a domestic animal
CA3124415A1 (en) 2018-12-21 2020-06-25 Northwestern University Use of annexins in preventing and treating muscle membrane injury
WO2020139977A1 (en) 2018-12-26 2020-07-02 Northwestern University Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder
JP7445640B2 (ja) * 2019-03-01 2024-03-07 神戸天然物化学株式会社 ミオスタチンスプライスバリアント由来タンパク質によるミオスタチンシグナル阻害とその利用
WO2025192635A1 (ja) * 2024-03-12 2025-09-18 リージョナルフィッシュ株式会社 魚類の肉質を改善する方法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1605763A (en) 1926-11-02 Garment retainer
US2754818A (en) 1950-06-24 1956-07-17 Scherer Corp R P Hypo jet injector
US3330276A (en) 1963-10-07 1967-07-11 Scherer Corp R P Hypodermic jet injector
US3788315A (en) 1971-04-20 1974-01-29 S Laurens Disposable cutaneous transjector
US3853125A (en) 1971-10-05 1974-12-10 W Clark Disposable needleless injector
US4491632A (en) 1979-10-22 1985-01-01 The Massachusetts General Hospital Process for producing antibodies to hepatitis virus and cell lines therefor
US4310550A (en) 1979-10-26 1982-01-12 Pfizer Inc. Lipid amines formulated with fat or lipid emulsions as vaccine adjuvants
US4431739A (en) 1979-11-05 1984-02-14 Genentech, Inc. Transformant bacterial culture capable of expressing heterologous protein
US4425437A (en) 1979-11-05 1984-01-10 Genentech, Inc. Microbial polypeptide expression vehicle
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4338397A (en) 1980-04-11 1982-07-06 President And Fellows Of Harvard College Mature protein synthesis
DE3167442D1 (en) 1980-07-07 1985-01-10 Nat Res Dev Improvements in or relating to cell lines
US4341761A (en) 1980-07-25 1982-07-27 E. I. Du Pont De Nemours And Company Antibodies to immunogenic peptides and their use to purify human fibroblast interferon
US4466917A (en) 1981-02-12 1984-08-21 New York University Malaria vaccine
US4493890A (en) 1981-03-23 1985-01-15 Miles Laboratories, Inc. Activated apoglucose oxidase and its use in specific binding assays
JPS5873993U (ja) 1981-11-12 1983-05-19 三菱電機株式会社 ２気筒回転式圧縮機
US4399121A (en) 1981-11-04 1983-08-16 Miles Laboratories, Inc. Iodothyronine immunogens and antibodies
US4427783A (en) 1981-12-14 1984-01-24 Hoffmann-La Roche Inc. Immunoassay of thymosin α1
EP0138854B1 (en) 1983-03-08 1992-11-04 Chiron Mimotopes Pty. Ltd. Antigenically active amino acid sequences
US4518385A (en) 1983-06-13 1985-05-21 Preci-Tech Ltd. Disposable syringe for needleless injector
US4722840A (en) 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374426A (en) 1986-09-03 1994-12-20 University Of Saskatchewan Rotavirus nucleocapsid protein VP6 in vaccine compositions
US5055400A (en) 1986-11-26 1991-10-08 University Of Guelph Leukotoxin gene of pasteurella haemolytica
US4957739A (en) 1987-08-13 1990-09-18 Board Of Regents, The University Of Texas System Pharmaceutical compositions of a 105 kD P. Haemolytica derived antigen useful for treatment of Shipping Fever
US5151267A (en) 1988-07-15 1992-09-29 University Of Saskatchewan Bovine herpesvirus type 1 polypeptides and vaccines
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
CA2014033C (en) 1989-04-07 1993-02-09 Stephen D. Acres Compositions and treatments for pneumonia in animals
US5062830A (en) 1990-04-04 1991-11-05 Derata Corporation Dry disposable nozzle assembly for medical jet injector
US5204253A (en) 1990-05-29 1993-04-20 E. I. Du Pont De Nemours And Company Method and apparatus for introducing biological substances into living cells
US5149655A (en) 1990-06-21 1992-09-22 Agracetus, Inc. Apparatus for genetic transformation
US5837268A (en) 1991-10-16 1998-11-17 University Of Saskatchewan GnRH-leukotoxin chimeras
US5994618A (en) 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
JPH09507829A (ja) 1993-03-19 1997-08-12 ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン 増殖分化因子−８
EP1574577A3 (en) 1994-07-08 2006-06-14 The Johns Hopkins University School Of Medicine Growth differentiation factor-11
AU6274298A (en) 1997-02-05 1998-08-25 Johns Hopkins University School Of Medicine, The Growth differentiation factor-8
WO1999002667A1 (en) 1997-07-14 1999-01-21 University Of Liege Mutations in the myostation gene cause double-muscling in mammals
WO1999006559A1 (en) 1997-08-01 1999-02-11 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (gdf) receptors
AU1390999A (en) 1997-11-10 1999-05-31 Johns Hopkins University School Of Medicine, The Methods for detection of mutations in myostatin variants
CA2319703C (en) 1998-02-05 2005-09-20 The Johns Hopkins University School Of Medicine Growth differentiation factor-8
HUP0201861A3 (en) 1999-07-20 2004-07-28 Pharmexa As Method for down-regulating gdf-8 activity

Also Published As

Publication number Publication date
AR019818A1 (es) 2002-03-20
ATE352619T1 (de) 2007-02-15
EP2018871A1 (en) 2009-01-28
EP1770162A1 (en) 2007-04-04
EP1770162B1 (en) 2008-12-31
CA2323607A1 (en) 1999-08-26
WO1999042573A1 (en) 1999-08-26
ES2527410T3 (es) 2015-01-23
EP2018871B1 (en) 2014-10-08
DE69934970D1 (de) 2007-03-15
PT1056845E (pt) 2007-04-30
CA2323607C (en) 2009-12-22
KR20010041111A (ko) 2001-05-15
NZ506911A (en) 2003-09-26
AU2507399A (en) 1999-09-06
DK1770162T3 (da) 2009-04-14
US20030065137A1 (en) 2003-04-03
CY1108074T1 (el) 2014-02-12
ES2318654T3 (es) 2009-05-01
EP1056845A1 (en) 2000-12-06
CY1108889T1 (el) 2014-07-02
DK1056845T3 (da) 2007-05-29
US6369201B1 (en) 2002-04-09
PT1770162E (pt) 2009-03-24
DE69934970T2 (de) 2007-10-25
EP1056845B1 (en) 2007-01-24
DE69940230D1 (de) 2009-02-12
AU765014B2 (en) 2003-09-04
ES2280115T3 (es) 2007-09-01
JP2002504326A (ja) 2002-02-12
CA2687533C (en) 2016-02-02
CA2687533A1 (en) 1999-08-26
IL137831A0 (en) 2001-10-31
ATE419353T1 (de) 2009-01-15
ZA991369B (en) 1999-08-20

Similar Documents

Publication Publication Date Title
BR9907995A (pt) Métodos imunológicos para modular miostatina em sujeitos vertebrados
BG101118A (en) Therapeutical compounds
BG99261A (en) Steroid glycosides for the treatment of hyperchlesterolemia
ES2178000T3 (es) Composiciones y metodos para tratar infecciones usando analogos de indolicidina.
EA199901031A1 (ru) Производные бензимидазола
DE69429527D1 (de) Inhibitoren von beta-amyloid-protein-herstellung
NO304982B1 (no) Fosfolipid, fosfatidyletanolamin, farmas°ytisk, nµrings eller kosmetisk blanding omfattende nevnte fosfolipid eller fosfatidyletanolamin
DE69027865D1 (de) ZUSAMMENSETZUNGEN enthaltend omega Conotoxin Peptide Derivate und deren Verwendung ZUR BEHANDLUNG VON ISCHÄMIE-ARTIGEN NEURONALEN SCHÄDIGUNGEN
FI953442A0 (fi) Gonadotropiinia sisältäviä pakastekuivattuja pallosia
BG101715A (bg) Тетрациклени спиросъединения,метод за тяхното получаване и приложението им като 5нт долу 1d рецепторни антагонисти
ATE210127T1 (de) 6-substituierte mycophenolsäurederivate mit immun suppressiver wirkung
GR3015513T3 (en) Use of baclofen for the preparation of medicaments for the treatment of angina pectoris.
FI910413A7 (fi) Tooppiset valmisteet ihmisen kynsien hoitamiseksi
ES2182914T3 (es) Inmunopotenciacion inducida de quitosan.
NO964238L (no) Halofantrin-fri-base for behandling av malaria og blandinger
DK0553294T3 (da) Fremstillingen af sammensætninger til behandlingen af celleproliferationssygdomme
NO983177L (no) Anvendelse av 1-enantiomeren av centkroman til fremstilling av et farmasaytisk preparat for behandling eller profylakse av brystkreft
IT1230068B (it) Procedimento per la preparazione di n sulfoniluree.
ATE151774T1 (de) Cyclopentanperhydrophenanthren-17-beta-(3-furyl - 3-derivate und pharmazeutische präparate davon, zur behandlung von kardiovaskulär-erkrankungen
DE69621786D1 (de) Aminotetralinderivat zur behandlung von herzkreislauferkrankung
IT1288399B1 (it) Medicamento per il trattamento terapeutico della maculopatia legata all'eta', della maculopatia non legata all'eta' e per la profilassi
NZ216519A (en) Polycyclic compounds and pharmaceutical compositions
SE8402199L (sv) Farmaceutiskt preparat innehallande co-dergocrin och en kalciumantagonist
DK0858345T3 (da) Anvendelse af muteiner af vildtypecytokiner som immunogener
FI872459A7 (fi) Farmaseuttinen valmiste bakteeri-infektioiden hoitoon.

Legal Events

Date Code Title Description
PCP Transfer pending
PC Transfer

Owner name: METAMORPHIX INTERNATIONAL, INC. (US)

B25G Requested change of headquarter approved

Owner name: METAMORPHIX INTERNATIONAL, INC. (US)

Free format text: ALTERADA A SEDE DO TITULAR, CONFORME REQUERIDO NA PETICAO NO 015309/RJ DE 22/03/2004.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 10 (VIII E IX), 11, 13 E 18 (III) DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time